Journal article
The use of inhaled prostaglandins in patients with ARDS: a systematic review and meta-analysis
Chest, Vol.147(6), pp.1510-1522
06/2015
DOI: 10.1378/chest.14-3161
PMCID: PMC4451707
PMID: 25742022
Abstract
This study aimed to determine whether inhaled prostaglandins are associated with improvement in pulmonary physiology or mortality in patients with ARDS and assess adverse effects.
The following data sources were used: PubMed, EMBASE, CINAHL, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, reference lists, conference proceedings, and ClinicalTrials.gov. Studies selected included randomized controlled trials and nonrandomized studies. For data extraction, two reviewers independently screened titles and abstracts for eligibility. With regard to data synthesis, 25 studies (two RCTs) published over 21 years (1993-2014) were included. The PROSPERO registration number was CRD42014013180.
One randomized controlled trial showed no difference in the change in mean Pao2 to Fio2 ratio when comparing inhaled alprostadil to placebo: 141.2 (95% CI, 120.8-161.5) to 161.5 (95% CI, 134.6-188.3) vs 163.4 (95% CI, 140.8-186.0) to 186.8 (95% CI, 162.9-210.7), P = .21. Meta-analysis of the remaining studies demonstrated that inhaled prostaglandins were associated with improvement in Pao2 to Fio2 ratio (16 studies; 39.0% higher; 95% CI, 26.7%-51.3%), and Pao2 (eight studies; 21.4% higher; 95% CI, 12.2%-30.6%), and a decrease in pulmonary artery pressure (-4.8 mm Hg; 95% CI, -6.8 mm Hg to -2.8 mm Hg). Risk of bias and heterogeneity were high. Meta-regression found no association with publication year (P = .862), baseline oxygenation (P = .106), and ARDS etiology (P = .816) with the treatment effect. Hypotension occurred in 17.4% of patients in observational studies.
In ARDS, inhaled prostaglandins improve oxygenation and decrease pulmonary artery pressures and may be associated with harm. Data are limited both in terms of methodologic quality and demonstration of clinical benefit. The use of inhaled prostaglandins in ARDS needs further study.
Details
- Title: Subtitle
- The use of inhaled prostaglandins in patients with ARDS: a systematic review and meta-analysis
- Creators
- Brian M Fuller - Department of Anesthesiology, Division of Critical Care, Department of Emergency Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO. Electronic address: fullerb@wusm.wustl.eduNicholas M Mohr - Departments of Emergency Medicine and Anesthesiology, Division of Critical Care, Roy J. and Lucille A. Carver College of Medicine, The University of Iowa, Iowa City, IALee Skrupky - Department of Pharmacy, Aurora BayCare Medical Center, Green Bay, WISusan Fowler - Bernard Becker Medical Library, Washington University School of Medicine in St. Louis, St. Louis, MOMarin H Kollef - Department of Medicine, Division of Pulmonary and Critical Care Medicine, Washington University School of Medicine in St. Louis, St. Louis, MOChristopher R Carpenter - Department of Emergency Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO
- Resource Type
- Journal article
- Publication Details
- Chest, Vol.147(6), pp.1510-1522
- DOI
- 10.1378/chest.14-3161
- PMID
- 25742022
- PMCID
- PMC4451707
- NLM abbreviation
- Chest
- ISSN
- 0012-3692
- eISSN
- 1931-3543
- Publisher
- United States
- Grant note
- KL2 TR000450 / NCATS NIH HHS UL1 TR000448 / NCATS NIH HHS
- Language
- English
- Date published
- 06/2015
- Academic Unit
- Epidemiology; Emergency Medicine; Anesthesia; Injury Prevention Research Center
- Record Identifier
- 9984025280202771
Metrics
37 Record Views